ULTI_1170x120_2-25-20

Dr. Reddy’s launches sevelamer carbonate for oral suspension in U.S.

Print Friendly, PDF & Email

PRINCETON, N.J. — Dr. Reddy’s Laboratories announced the launch of sevelamer carbonate for oral suspension, in 0.8 g and 2.4 g packets, a therapeutic equivalent generic version of Renvela (sevelamer carbonate) for oral suspension, approved by the U.S. Food and Drug Administration.

The Renvela brand and generic had U.S. sales of approximately $101 million MAT for the most recent twelve months ending in October 2018 according to IMS Health.

Dr. Reddy’s sevelamer carbonate for oral suspension is available in 0.8 g and 2.4 g packets in count size of 90.


EMC_728x90

TRP_728x90_12-19-19

Comments are closed.